Recent Updates
Recently added Catalysts
AGIO

Agios to Webcast Conference Call of Second Quarter 2018 Financial Results on August 2, 2018

Key Takeaway: CAMBRIDGE, Mass., July 23, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will host a conference call and live webcast on Thursday, August

Full Press Release Details

CAMBRIDGE, Mass., July 23, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will host a conference call and live webcast on Thursday, August 2, 2018 at 8:00 a.m. ET to report its second quarter financial results and discuss recent clinical development and corporate activities.
A live webcast can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. The conference call can be accessed by dialing 1-877-377-7098 (domestic) or 1-631-291-4547 (international) and referring to conference ID 1497883. The webcast will be archived and made available for replay on the company's website beginning approximately two hours after the event.
Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has two approved oncology precision medicines and multiple first-in-class investigational therapies in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit the company's website at www.agios.com.
Agios Investors Contact:
Renee Leck, 617-649-8299
Senior Manager, Investor Relations
Agios Media Contact:
Holly Manning, 617-844-6630
Associate Director, Corporate Communications
Last updated: Jul 23, 2018